drugset / Trial / NCT00036244

Synthetic Human Secretin in Children With Autism

NCT00036244 ↗

Phase 3 Completed Repligen Corporation
RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of the study is to determine whether multiple doses of secretin are safe and effective in the treatment of children with autism.

Timeline

Start
2002-04
Primary completion
—
Completion
2004-01

Drugs

EvaluationDrugModalityDoseRoute
Subject RG1068 Peptide — —

Indications